Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291564 | 0.88 | POLB (0.45) | CYP4F2CYP4A11CYP11B1CYP11B2ADRB2 | |
| SCHEMBL22242096 | 0.86 | CYP11B1 (0.41) | CYP4F2CYP4A11CYP11B1CYP11B2ADRB2 | |
| SCHEMBL29108309 | 0.84 | CYP4F2 (0.53) | CYP4F2CYP4A11CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL30640107 | 0.84 | CYP4F2 (0.53) | CYP4F2CYP4A11CYP11B1CYP11B2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11132194 | 0.84 | CYP4F2 (0.59) | CYP4F2CYP4A11P4HTMALDH1A1MAPT | |
| SCHEMBL24347855 | 0.81 | ADRB2 (0.43) | CYP11B1CYP11B2ADRB2ADRB1P4HTM | |
| SCHEMBL4734773 | 0.81 | TSHR (0.51) | CYP4F2CYP4A11CYP11B1CYP11B2ADRB2 | |
| SCHEMBL29027272 | 0.80 | P4HTM (0.62) | P4HTMLMNA | |
| SCHEMBL20037758 | 0.79 | CYP11B1 (0.43) | CYP4F2CYP4A11CYP11B1CYP11B2ADRB2 | |
| SCHEMBL15820303 | 0.79 | CYP11B1 (0.48) | CYP4F2CYP4A11CYP11B1CYP11B2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| CN-104151200-B | Hdac inhibitor | 葛兰素史克知识产权发展有限公司 | 2017-06-20 | — | — | CN | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | disclosed |
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20130197042-A1 | HDAC INHIBITORS | CHROMA THERAPEUTCS, LTD | 2013-08-01 | — | — | US | disclosed |
| US-20130197042-A1 | HDAC INHIBITORS | CHROMA THERAPEUTCS, LTD | 2013-08-01 | — | — | US | disclosed |
| US-20130197042-A1 | HDAC INHIBITORS | CHROMA THERAPEUTCS, LTD | 2013-08-01 | — | — | US | disclosed |
| EP-2295410-A1 | HDAC inhibitor | Chroma Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295410-A1 | HDAC inhibitor | Chroma Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010010-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| CN-101528677-A | HDAC inhibitors | CHROMA THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | CN | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010010-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | CYP4F2 2225/4885CYP4A11 1707/4885CYP11B1 1614/4885 |
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | CYP4F2 3368/4885CYP4A11 2489/4885CYP11B1 1756/4885 |
| US-20130197042-A1 | HDAC INHIBITORS | HDAC1, HDAC3, HDAC2 | CYP4F2 2271/4885CYP4A11 1777/4885CYP11B1 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.